Image Source: jenburkt.com
Jenburkt Pharmaceuticals Ltd has announced today that its Board of Directors has proposed a final dividend of ₹18 each per share for the financial year ended March 31, 2025. This approval was made alongside the approval of the company’s audited financial results for the financial year for the fourth quarter and for FY2025.
The Board convened on May 20, 2025, was satisfied with the company's performance and the solid financial results from operations achieved during the year. The Board's recommended dividend shows Jenburkt Pharmaceuticals’ commitment to returning reliable value to its shareholders and it is an increase from the last dividends repaid.
Jenburkt Pharmaceuticals’ audited corporations attributes for Q4 and FY2025 demonstrated strong growth across multiple key financial metrics, supported by strong performance from operations and continued improvement in demand for the Pharmaceuticals business products. The Board’s recommended dividends of 18 demonstrates the Board’s representation that it is confident in the Company’s estimates and continued to have a healthy cash position.
The dividend is subject to shareholder approval at the next upcoming Annual General Meeting. The declaration date and the date of payment to shareholders will be announced at a later date.
Source: ReutersJenburkt Pharmaceuticals Ltd has announced today that its Board of Directors has proposed a final dividend of ₹18 each per share for the financial year ended March 31, 2025. This approval was made alongside the approval of the company’s audited financial results for the financial year for the fourth quarter and for FY2025.
The Board convened on May 20, 2025, was satisfied with the company's performance and the solid financial results from operations achieved during the year. The Board's recommended dividend shows Jenburkt Pharmaceuticals’ commitment to returning reliable value to its shareholders and it is an increase from the last dividends repaid.
Jenburkt Pharmaceuticals’ audited corporations attributes for Q4 and FY2025 demonstrated strong growth across multiple key financial metrics, supported by strong performance from operations and continued improvement in demand for the Pharmaceuticals business products. The Board’s recommended dividends of 18 demonstrates the Board’s representation that it is confident in the Company’s estimates and continued to have a healthy cash position.
The dividend is subject to shareholder approval at the next upcoming Annual General Meeting. The declaration date and the date of payment to shareholders will be announced at a later date.
Source: Reuters
Advertisement
Advertisement
